Taken together these data demonstrate that glucose oxidative metabolism is distinct in primary CML CD34+CD38- cells compared with normal CD34+CD38− cells, and mitochondrial pyruvate metabolism can be inhibited with a clinically relevant MPC1/2 inhibitor. This evidence concerns the gene CD38 and chronic myelogenous leukemia, BCR-ABL1 positive.